Patent
Anti-angiogenic compositions and methods of use
Reads0
Chats0
TLDR
In this article, an anti-angiogenic factor and a polymeric carrier were used for embolization of blood vessels and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.Abstract:
The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.read more
Citations
More filters
Patent
Method for loading nanoporous layers with therapeutic agent
Gary K. Owens,Brian R. Wamhoff,Matthew Hudson,Whye-Kei Lye,Joshua Spradlin,Michael Reed,Kareen Looi +6 more
TL;DR: In this paper, the authors proposed a method for loading of drugs and other therapeutic agents into nanoporous coatings, including vascular stents, having at least one porous layer adapted to resist stenosis or cellular proliferation without requiring elution of therapeutic agents.
Patent
Implantable medical device with beneficial agent concentration gradient
TL;DR: In this paper, a matrix is formed such that the concentration of the therapeutic agent in the matrix varies as a gradient relative to a surface of the implantable body, which directly controls the rate of elution of the agent from the matrix.
Patent
Compositions containing fast-leaching plasticizers for improved performance of medical devices
TL;DR: Medical implants containing a temporary plasticizer, methods of producing such implants, and methods of using the implants in treating a disease, or ameliorating one or more symptoms thereof, in a subject are provided in this article.
Patent
Coated medical device
TL;DR: A stent that is adapted for introduction into a body passageway and which releases at least one biological agent after being inserted in the body passage can be a controlled release via molecular diffusion through a non-porous polymer layer as discussed by the authors.
Patent
Manufacturing process for polymeric stents
TL;DR: In this article, a method of fabricating a stent delivery device is disclosed, which comprises forming a polymeric tube by using extrusion, the tube being drawn during extrusion so that a diameter of the formed tube is less than a target diameter; radially deforming the formed polymeric tubes so that the deformed tube comprises the target diameter.
References
More filters
Journal ArticleDOI
The pathogenesis of atherosclerosis: a perspective for the 1990s
TL;DR: The ability to control the expression of genes encoding these molecules and to target specific cell types provides opportunities to develop new diagnostic and therapeutic agents to induce the regression of the lesions and, possibly, to prevent their formation.
Journal ArticleDOI
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.
TL;DR: It is shown that vascular endothelial growth factor (VEGF) probably functions as a hypoxia-inducible angiogenic factor and is specifically induced in a subset of glioblastoma cells distinguished by their immediate proximity to necrotic foci and the clustering of capillaries alongside VEGF-producing cells.
Journal ArticleDOI
A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease
Patrick W. Serruys,P. de Jaegere,Ferdinand Kiemeneij,Carlos Macaya,Wolfgang Rutsch,Gr. Heyndrickx,H. Emanuelsson,Jean Marco,Victor Legrand,P. Materne +9 more
TL;DR: The clinical and angiographic outcomes were better in patients who received a stent than in those who received standard coronary angioplasty, however, this benefit was achieved at the cost of a significantly higher risk of vascular complications at the access site and a longer hospital stay.
Journal ArticleDOI
A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease
David L. Fischman,Martin B. Leon,Donald S. Baim,Richard A. Schatz,Michael P. Savage,Ian M. Penn,Katherine D. Detre,Lisa Veltri,Donald R. Ricci,Masakiyo Nobuyoshi,Michael W. Cleman,Richard R. Heuser,David Almond,Paul S. Teirstein,R. David Fish,Antonio Colombo,Jeffrey C. Brinker,Jeffrey Moses,Alex Shaknovich,John N. Hirshfeld,Stephen Bailey,Stephen E. Ellis,Randal Rake,Sheldon Goldberg +23 more
TL;DR: In selected patients, placement of an intracoronary stent, as compared with balloon angioplasty, results in an improved rate of procedural success, a lower rate of angiographically detected restenosis, a similar rate of clinical events after six months, and a less frequent need for revascularization of the original coronary lesion.
Journal ArticleDOI
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.
Donald R. Senger,Stephen J. Galli,Ann M. Dvorak,Carole A. Perruzzi,V. Susan Harvey,Harold F. Dvorak +5 more
TL;DR: Tumor ascites fluids from guinea pigs, hamsters, and mice contain activity that rapidly increases microvascular permeability, and this activity is secreted by these tumor cells and a variety of other tumor cell lines in vitro.